Professional Research
Kenneth B. Kummerfeld, MD

Undergraduate research in Tumor Immunology, 1974-1975

Sub-Investigator

• SADHART (Sertraline Antidepressant Heart Attack Randomized Trial) - A Randomized, Double-blind, Placebo-controlled Trial of Sertraline (Zoloft) for Major Depression after Acute Coronary Syndromes: Myocardial Infarction or Unstable Angina
• Val-HeFT - A Multi-country, Randomized, Double-blind, Parallel, Placebo- Controlled Trial to Assess the Effect of Valsartan on Morbidity, Mortality, Signs and Symptoms, and Quality of Life in Patients with Stable, Chronic Congestive Heart Failure (NYHA Class II-IV)
• CAPRICORN - A Multi-national, Multi-center, Randomized, Double-blind, Parallel Group Study to Determine the Effects of Carvedilol on Mortality in Patients with Left Ventricular Dysfunction, With or Without Clinical Evidence of Heart Failure, Post-myocardial Infarction
• GUARDIAN - A Double-blind, Placebo-controlled, Multi-national Trial to Investigate the Effect of the Na+/H+ Exchange Inhibitor HOE642 (Cariporide) on All-cause Mortality and Myocardial Infarction in Patients at Risk of Myocardial Necrosis Due to Acute Coronary Syndrome Related to the Disease Process or to an Interventional Cardiac Procedure
• PARAGON B - A Randomized, Double-blind, Placebo-controlled Study of Lamifiban (Ro 44-9883) in Patients with Unstable Angina/Non Q-wave Myocardial Infarction
• SPEED - (Strategies for Patency Enhancement in the Emergency Department) A Phase II, Randomized, Open-label, Angiographic Trial Evaluating the Benefit of ReoPro Bolus Plus 12-Hour Infusion With and Without Thrombolytic Therapy for Acute Myocardial Infarction
• HALT MI - A Phase 2 Safety and Efficacy Study of Hu23F2G in Patients With Acute Myocardial Infarction Treated with Direct Angioplasty
• INTRO AMI - A Pilot Phase II Safety and Efficacy Evaluation of Eptifbatide (Integrelin) in Patients Receiving Low Dose and Standard Dose Thrombolytic Therapy (Alteplase) for Acute Myocardial Infarction
• LIMIT AMI - A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Angiographic Trial of Safety and Efficacy of rhuMAb CD18 in Acute Myocardial Infarction
• GUSTO IV ACS - A Phase III, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of ReoPro, Given as a Bolus Followed By a 24 or 48 Hour Infusion, for the Treatment of Acute Coronary Syndrome Without ST Segment Elevation
• GUSTO IV AMI - A Phase III, Randomized, Open-label Trial Evaluating the Efficacy and Safety of ReoPro®(Abciximab) in Combination with Reduced Dose Retavase®/Rapilysin™(Recombinant Plasminogen Activator, Retaplase, r-PA) for the Treatment of Acute Myocardial Infarction
• AMISTAD II - A Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of Adenosine (Pallacor®, Adenosine Injection) As and Adjunct to Reperfusion Therapy (Thrombolysis or Mechanical Reperfusion) in the Treatment of Acute Anterolateral Myocardial Infarction
• A to Z - A Multi-center, Randomized, Controlled, Double-blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment with Simvastatin 40 mg Daily for 30 Days Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction with Aspirin
• BRACCO - A Clinical Evaluation to Determine the Optimal Imaging Parameters for Tc-99m Teboroxime in Subjects with Coronary Artery Disease and Subjects with No Evidence of Coronary Artery Disease
• TARGET - A Randomized, Multi-center, Double-blind, Abciximab-controlled Study to Evaluate the Efficacy of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention with Intracoronary Stent Placement
• CREDO - A Double-blind, Randomized Trial of Clopidigrel 300 mg Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily Compared with Placebo Loading Dose and Aspirin 325 mg Followed by Clopidigrel 75 mg and Aspirin Daily for the Prevention of Vascular Events and All-cause Mortality in Patients Undergoing Percutaneous Coronary Intervention
• GOLD - A Prospective, Multi-center, Observational Study Evaluating Platelet Function with the Accumetrics Ultegra-Rapid Platelet Function Assay (RPFA) in Patients Undergoing Coronary Interventions Using Platelet Glycoprotein IIb/IIIa Inhibitors
• POSTIT - Boston Scientific Scimed, Inc.-Post Market Research Study on the NIR Stent and Other Commercially Available Coronary Stents
• BRAVO - Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion
• CHARM (Candesarten Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity) - Studies of Candesartan in Patients with Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function (0003), Who Are Treated With ACE Inhibitors and Have Depressed Left Ventricular Systolic Function (0006), and Patients with Heart Failure Who Have Preserved Left Ventricular Function (0007)
• VALIANT (Valsartan in Acute Myocardial Infarction) - A Multi-national, Multi-center, Double-blind, Randomized, Active-controlled, Parallel Group Study Comparing the Efficacy and Safety of Long-term Treatment with Valsartan, Captopril, and Their Combination in High-risk Patients After Myocardial Infarction
• RAFT - A Double-blind, Placebo-controlled, Randomized Clinical Trial of Slow Release Propafenone (Rythmol®SR) in the Prevention of Symptomatic Recurrences of Atrial Fibrillation
• OVERTURE - Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events
• WIZARD - A Randomized, Double-blind, Placebo-controlled Trial of the Effect of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae